Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
under conditions in which the only other kinase tested that is significantly inhibited is MSK1 whose activity is reduced ~5-fold
C[C@@](O)([C@H](CC([O-])=O)C([O-])=O)C([O-])=O
Chemical Name: 2-({1-[13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6
which treats illnesses associated with rapid heartbeats such as atrial and ventricular arrhythmias
1219707-39-7
Regorafenib Catalog No.:M10913-10 under conditions in which theRegorafenib, also known as BAY 73 4506 ; is a n orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic
US$ 25.95
US$ 59.95
US$ 21.95